GENEDX HOLDINGS CORP CLASS A (WGS)
Health Care · Genetic Testing & Diagnostics · NASDAQ
GeneDx uses AI-powered genomics to provide precise, actionable clinical genetic testing for rare and complex diseases.
What GENEDX HOLDINGS CORP CLASS A does
GeneDx Holdings Corp. is a genomics company focused on providing actionable clinical genetic testing. The company leverages artificial intelligence and data-driven insights to deliver diagnostic solutions for rare diseases and complex clinical conditions.
Themes: genomics, artificial intelligence in healthcare, rare disease diagnostics, precision medicine
Fundamentals
- Price$87.07 as of 2026-08-21 close
- Market cap$2.6B as of 2026-08-21
- 1-year return-27.9% 2025-08-21 close $120.72 → 2026-08-21 close $87.07
- P/En/a negative earnings
- Net margin-23.4% as of 2026-08-24
- Gross margin+69.4% as of 2026-08-24
- ROE-38.7% as of 2026-08-24
- Debt / equity0.40 as of 2026-08-24
- Revenue growth (YoY)+25.4% as of 2026-08-24
- Revenue CAGR (3y)+22.1% SEC XBRL
- Beta1.98 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How WGS compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
WGS is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
51.8 #677 of 1,704 scored · #122 of 240 in Health Care
Trend 78th: it is trading 28.7% above its 50-day average, the short-term trend line; catalysts 76th: analysts have raised their average price target by 5.3% since the prior reading; weakest is volume and participation 43rd: trading volume is about normal versus its 30-day average. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How GENEDX HOLDINGS CORP CLASS A looks technically
GENEDX HOLDINGS CORP CLASS A (WGS) is trading 0.7% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 122 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 71, in overbought territory (above 70). It just made a new 20-day high, its first since 2026-03-10, pushing above its recent trading range. It is 49.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 0.7% below its 200-day average, the long-term trend line — a long-term downtrend | -0.7% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $67.67 | $67.67 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $87.68 | $87.68 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 72.95. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 122 trading days ago — a "death cross", a bearish long-term signal | 122 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 31.4 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 71, in overbought territory (above 70) | 70.9 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($64.28 to $87.17) — its "stochastic" reading is 100 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 99.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 15 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $170.87 | $170.87 |
|---|---|---|
| From the 52-week high | it is 49.0% below its 52-week high (its highest price of the past year) | -49.0% |
| Above the 52-week low | it is 170.3% above its 52-week low (its lowest price of the past year) | +170.3% |
| Below the 52-week high | it is 49.0% below its highest point of the past year | 49.0% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-03-10, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2026-03-10, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $896.94 (set on 2021-02-12) | $896.94 |
| Given back of the 52-week move | over the past year its closes ranged ($34.51 to $167.51), and it has recovered roughly a third of its fall from last year’s high — 40% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $116.71 to $120.96. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 39.5% |
| From the all-time high | it is 90.3% below its all-time high | -90.3% |
| Nearest price level | it is trading 1.4% below a resistance level at $88.27 — a price it turned at three times since 2024-10-30, most recently on 2025-04-21. Since 2024-08-21 it has 8 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.4% |
| All-time low | its lowest closing price on record is $1.16 (set on 2023-11-16) | $1.16 |
| Above the all-time low | it is 7405.6% above its all-time low | +7,406% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 66th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $5.05 between its high and its low — about 5.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $5.05 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $58.97 and $88.81 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $58.97 – $73.89 – $88.81 |
| Typical daily range (% of price) | its price moves about 5.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 0.1 daily ranges below its 200-day average price (0.7% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.71× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 5.3% since the prior reading | +5.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.4% |
|---|---|---|
| Open gap | it gapped 2.6% above the previous close 2 sessions ago and has not traded back through the level it left behind at 76.34 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.6% |
| Gap filled | a 2.8% gap down opened on 2026-08-06 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +14.05% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 38.9 percentage points (the stock gained 41.2% while the market gained 2.3%) | +38.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 80.9 percentage points (the stock gained 84.0% while the market gained 3.1%) | +80.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 5.0 percentage points (the stock gained 6.1% while the market gained 11.1%) | -5.0% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 48.4 percentage points (the stock lost 27.9% while the market gained 20.5%) | -48.4% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, its RSI momentum gauge is overbought (a stretched reading), lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 35% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 13.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +35.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 33% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $65.61 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | +32.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 16% above the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $74.95 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | +16.2% |
Price levels it has turned at before
WGS last closed at $87.06 on 2026-08-21. Since 2024-08-21 it has turned at 8 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $88.27 | Resistance | 1.4% above the last close | turned there three times · 2024-10-30 to 2025-04-21 |
| $84.14 | Support | 3.4% below the last close | turned there three times · 2024-12-06 to 2026-08-12 |
| $82.52 | Support | 5.2% below the last close | turned there four times · 2024-11-11 to 2026-02-06 |
| $95.69 | Resistance | 9.9% above the last close | turned there twice · 2025-06-25 to 2026-03-09 |
| $76.12 | Support | 12.6% below the last close | turned there twice · 2025-06-03 to 2025-07-22 |
| $107.36 | Resistance | 23.3% above the last close | turned there twice · 2025-03-03 to 2025-03-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $72.95.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $72.95 and $77.80 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Overbought (14-day RSI above 70) · Pulled back from the 12-month high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.11 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$90.44 range $74.00 – $103.00; median $90.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for WGS
- Consensus EPS estimate$0.0725 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses and uncertainty regarding achieving sustained profitability.","Dependence on third-party payor reimbursement and coverage decisions.","Significant competition and the need to maintain rapid technological innovation in clinical testing."]
What changed in the latest 10-Q
AI-assisted comparison of WGS's 10-Q filed 2026-05-04 against the prior one filed 2025-10-28.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to 2025 Form 10-K for year ended December 31, 2025 (in newer filing dated 2026-05-04)
- Test volume metric: 27,488 exome and genome tests in Q1 2026 representing 50% of all test results (in newer filing)
- Comparison metric: approximately 20,562 exome and genome tests in Q1 2025 representing 40% of all test results (in newer filing)
- Detailed explanation that test volume correlates with genomic database size and long-term patient relationships (in newer filing)
- Statement that resulted tests enable identification of variants of unknown significance and population-specific insights (in newer filing)
- Explanation of workflow completion and revenue recognition timing (in newer filing)
- Details on payor decision-making factors including medical necessity, cost-effectiveness, and prior authorization (in newer filing)
- Explanation of varying procedural requirements across different payors (in newer filing)
- Language regarding potential denial of payment or recoupment by third-party payors (in newer filing)
- Statement on focus to expand coverage for exome and genome tests and future tests (in newer filing)
- References to Item 1A Risk Factors in quarterly report and Part I Item 1A Risk Factors in 2025 Form 10-K (in newer filing)
- Removed:
- Reference to 2024 Form 10-K for year ended December 31, 2024 (in older filing dated 2025-10-28)
- Phrase 'on the Company's history' following Note 1 reference (in older filing)
- Incomplete sentence fragment: 'See the section titled "' at end of Factors Affecting Our Performance (in older filing)
- Reworded:
- Form reference changed from '2024 Form 10-K' to '2025 Form 10-K' with updated fiscal year
- Note 1 reference expanded from listing company history to full title 'Organization and Description of Business'
- Risk Factors incorporation language expanded to explicitly include 'Part I, Item 1A "Risk Factors" in our 2025 Form 10-K, which are incorporated by reference in this Quarterly Report'
- Notes:
- Older filing text appears truncated at 'See the section titled "' suggesting incomplete or corrupted source
- Comparison limited to content available in both filings; older filing excerpt is significantly shorter
Risk Factors
- Added:
- Added forward-looking statement about 'the use of artificial intelligence ("AI")' in context of Fabric Genomics acquisition benefits (filed 2026-05-04)
- Added reference to 'armed conflict' as unforeseen circumstance affecting business operations (filed 2026-05-04)
- Removed:
- Removed bullet point about 'our plans to pursue a new strategic direction, and the cost savings and impact on our gross margins from exiting our reproductive and women's business and our somatic tumor testing business' (filed 2025-10-28)
- Removed reference to 'armed conflict' from the list of unforeseen circumstances; text now reads 'natural disasters' without 'armed conflict' in older version context
- Reworded:
- Changed 'our expectations for generating revenue, incurring losses, and remaining profitable on a sustained basis' to 'our expectations for generating revenue, incurring losses, and profitability on a sustained basis' (filed 2026-05-04)
- Changed 'our ability to realize the expected benefits of our acquisition of Fabric Genomics, Inc. ("Fabric Genomics")' to include 'and the use of artificial intelligence ("AI")' (filed 2026-05-04)
- Notes:
- The two filings cover different reporting periods (Q1 2026 vs Q3 2025) and financial data is not directly comparable
- Forward-looking statements section is the only Risk Factors content provided; full Item 1A Risk Factors detail not included in source texts
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
2 open-market purchases and 9 open-market sales by insiders in the last 90 days.
- Last 90 days2 buys ($11M) · 9 sells ($1M) — 1 buying, 2 selling insiders
- Last 180 days24 buys ($93M) · 12 sells ($1M) — 2 buying, 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-16. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about WGS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding WGS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 4,565,074
- Reported value $293,169,084
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
WGS had 5,848,506 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
WGS had 19.6% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.58 days to cover at the same settlement.
- Reported short interest (shares) 5,848,506
- Short interest (% of shares outstanding) 19.6%
- Prior settlement (shares) 5,830,669
- Reported change 0.31%
- Days to cover (reported) 8.58
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Invitae
- Natera (NTRA)
- Guardant Health (GH)
- Exact Sciences (EXAS)
- Myriad Genetics (MYGN)
- Illumina (ILMN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare WGS vs…
GENEDX HOLDINGS CORP CLASS A is found in…
Frequently asked questions
What does GENEDX HOLDINGS CORP CLASS A (WGS) do?
GeneDx Holdings Corp. is a genomics company focused on providing actionable clinical genetic testing. The company leverages artificial intelligence and data-driven insights to deliver diagnostic solutions for rare diseases and complex clinical conditions.
What sector is GENEDX HOLDINGS CORP CLASS A (WGS) in?
GENEDX HOLDINGS CORP CLASS A (WGS) is classified in the Health Care sector. Its industry is Genetic Testing & Diagnostics. It trades on NASDAQ.
Who are GENEDX HOLDINGS CORP CLASS A's (WGS) competitors?
Notable peers of GENEDX HOLDINGS CORP CLASS A (WGS) include Invitae, Natera, Guardant Health, Exact Sciences and Myriad Genetics. This peer set is informational only — not financial advice.
Is GENEDX HOLDINGS CORP CLASS A (WGS) overbought or oversold right now?
GENEDX HOLDINGS CORP CLASS A (WGS) is currently in overbought territory (its 14-day RSI is 71, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on WGS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.